Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / GLOW blend

GLOW blend: BPC-157, TB-500 and GHK-Cu

GLOW is a seller's name for one vial that holds three compounds: BPC-157, TB-500 and the copper peptide GHK-Cu. It is marketed for skin, healing and recovery. No human trial of the blend exists.

3 compounds · Not FDA-approved · Reviewed

Not approved by the FDA for human use. Not for human consumption. This page describes GLOW blend only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer

FDA status

BPC-157: Not approved for any use. FDA flagged it for safety concerns in 2023. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking. The use the committee considered was ulcerative colitis. FDA staff had advised that it did not meet the standard for listing. In October 2026 HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound it under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.

TB-500: Not approved for any use. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking. The use the committee considered was wound healing. In October 2026 HHS published a draft policy saying it does not intend to take action against pharmacies and physicians that compound it under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.

GHK-Cu: Not approved as a drug. FDA flagged the injectable form in 2023. An advisory committee review is expected before the end of February 2027.

Evidence

BPC-157: Almost entirely animal and laboratory studies. Published human data cover only a few dozen people.

TB-500: No published human trials of TB-500 itself. FDA has pointed out that human studies of thymosin beta-4 are not evidence for TB-500.

GHK-Cu: Some human evidence for topical use on skin. No human studies support injecting it.

No study has tested these compounds together in one vial in people.

Risks

BPC-157: Long-term safety in people is unknown. It is banned in sport at all times under the World Anti-Doping Code.

TB-500: Safety in people is unknown. It is banned in sport at all times under the World Anti-Doping Code.

GHK-Cu: FDA has cited a risk of immune reactions with injectable products because of possible aggregation and impurities.

Products sold for "research use only" carry no assurance of identity, strength or sterility. In a blend you cannot set the amounts separately: every draw carries each compound in the ratio mixed into the vial.

Sport

BPC-157: It is banned in sport at all times under the World Anti-Doping Code.

TB-500: It is banned in sport at all times under the World Anti-Doping Code.

GHK-Cu: It is not named on the 2026 WADA Prohibited List. Athletes should check any unapproved injectable with their anti-doping agency.

Related

Each compound has its own profile: BPC-157, TB-500, GHK-Cu. See also the Wolverine blend and the 2026 regulatory tracker.

Questions

What is in GLOW blend?

BPC-157, TB-500 and GHK-Cu.

Is GLOW blend FDA-approved?

No. There is no approved product combining these compounds, and BPC-157, TB-500, GHK-Cu are not approved for any use.

Sources: UCHealth Today: peptides, benefits, risks and FDA concerns (July 2026); NewBeauty: what to know about the GLOW peptide blend; AJMC: FDA panel backs 6 peptides for compounding; Pharmacy Times: what the peptide vote changes; Black Health: what the FDA peptide vote changed; HHS: enforcement discretion policy for compounding certain peptides (draft); Federal Register: HHS draft peptide compounding policy, October 30, 2026; Worst Pills, Best Pills: unapproved peptides; FDA: bulk drug substances that may present significant safety risks; WADA: 2026 Prohibited List.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.